Organisation paid for research Program year 2025 Source: CMS Open Payments

Compass Research East LLC

Neither a doctor nor a teaching hospital

Research payments

$2,208,213

72 payments

Through program year 2025, Compass Research East LLC is reported as receiving $2,208,213 in research payments, across 72 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $421,184 10
2024 Research $457,959 13
2023 Research $258,234 10
2022 Research $61,547 3
2021 Research $276,047 16
2020 Research $606,130 10
2019 Research $127,112 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,208,213 72 payments
Studies the money was for Research payments · program years 2019–2025
  1. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $780,443 11 payments
  2. A Study of Ly3298176 (Tirzepatide) for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities $520,837 4 payments
  3. A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly As Add-On Therapy to Metformin in Patients With Type 2 Diabetes $258,051 7 payments
  4. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $217,676 4 payments
  5. A Study of Ly3298176 (Tirzepatide) for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities $130,864 2 payments
  6. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $77,638 2 payments
  7. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $63,252 7 payments
  8. A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous Ly3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on A Stable Dose of Tirzepatide Or Semaglutide Who Failed to Achieve Hba1c Goal $46,522 1 payment
  9. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized Double-Blind Placebo-Controlled Trial (Surmount-1) $46,511 3 payments
  10. A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus $17,760 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record